Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and camrelizumab for first-line advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR1900028221Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib and camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Second Hospital of Lanzhou University. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900028221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028221.